BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Weiller E, Weiss C, Watling CP, Edge C, Hobart M, Eriksson H, Fava M. Functioning outcomes with adjunctive treatments for major depressive disorder: a systematic review of randomized placebo-controlled studies. Neuropsychiatr Dis Treat 2018;14:103-15. [PMID: 29343962 DOI: 10.2147/NDT.S146840] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Hobart M, Zhang P, Skuban A, Brewer C, Hefting N, Sanchez R, McQuade RD. A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder. J Clin Psychopharmacol 2019;39:203-9. [PMID: 30946704 DOI: 10.1097/JCP.0000000000001034] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
2 Kishi T, Sakuma K, Nomura I, Matsuda Y, Mishima K, Iwata N. Brexpiprazole as Adjunctive Treatment for Major Depressive Disorder Following Treatment Failure With at Least One Antidepressant in the Current Episode: a Systematic Review and Meta-Analysis. Int J Neuropsychopharmacol 2019;22:698-709. [PMID: 31350882 DOI: 10.1093/ijnp/pyz040] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Morton E, Bhat V, Giacobbe P, Lou W, Michalak EE, McInerney S, Chakrabarty T, Frey BN, Milev RV, Müller DJ, Parikh SV, Rotzinger S, Kennedy SH, Lam RW; CAN-BIND Investigator Team. Predictors of Quality of Life Improvement with Escitalopram and Adjunctive Aripiprazole in Patients with Major Depressive Disorder: A CAN-BIND Study Report. CNS Drugs 2021;35:439-50. [PMID: 33860922 DOI: 10.1007/s40263-021-00803-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Hobart M, Zhang P, Weiss C, Meehan SR, Eriksson H. Adjunctive Brexpiprazole and Functioning in Major Depressive Disorder: A Pooled Analysis of Six Randomized Studies Using the Sheehan Disability Scale. Int J Neuropsychopharmacol 2019;22:173-9. [PMID: 30508090 DOI: 10.1093/ijnp/pyy095] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]